Drug intelligence / Profile preview

RO’599

Development stage: Preclinical
Lead developer: OmniAb
Administration: Subcutaneous

Overview

RO’599 is an investigational preclinical compound with potential to treat various brain health diseases. It was acquired by Angelini Pharma from OmniAb in May 2025 through an asset purchase and assignment agreement, as part of Angelini's strategic effort to build its brain health pipeline.

Targets

KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)

Beyond the preview

Go deeper on RO’599.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO’599.

Explore the full profile